ArticleBreast cancer (Dove Medical Press)2026
The Correlation Between CD8+ Tumor-Infiltrating Lymphocytes and the Efficacy of Neoadjuvant Therapy in Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the correlation between the CD8+ tumor-infiltrating lymphocytes (TILs) expression and the efficacy of neoadjuvant therapy (NAT) in breast cancer, while previous studies have reported inconsistent findings regarding the predictive value of CD8+ TILs. Methods: Data from 94 breast cancer patients who underwent NAT between January 2017 and June 2019 were retrospectively analyzed. Preoperative CD8+ TILs expression was evaluated through immunohistochemistry, and its association with clinical and pathological responses to NAT was assessed. Results: Univariate analysis indicated that tumor stage, axillary lymph node status, and intratumoral CD8+ TILs were correlated with clinical complete response (cCR). Multivariate analysis identified intratumoral CD8+ TILs as an independent predictor of cCR (OR 3.038; p=0.02). Patients achieving pathological complete response (pCR) exhibited significantly higher intratumoral CD8+ TILs expression compared to those without (p=0.04). Univariate analysis also linked estrogen receptor (ER), progesterone receptor (PR), HER2 status, and intratumoral CD8+ TILs to pCR, with multivariate analysis confirming intratumoral CD8+ TILs as an independent predictor (OR 4.036; p=0.02). Conclusion: Our findings suggest that intratumoral CD8+ TILs are an independent predictor of the efficacy of neoadjuvant therapy in breast cancer. In the future, incorporating intratumoral CD8+ TILs into existing clinicopathological predictive models and combining their assessment with other immune biomarkers may enable the development of more robust predictive tools, thereby providing a solid foundation for truly individualized and precision-based neoadjuvant treatment in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.